108 - From Inactive to Reactive: When and How to Treat HBV Infection

10/4/2019

8:00 AM - 9:00 AM

Room: Walter E. Washington Convention Center, 147 AB

MOC Credit: Maximum of 1.0 hours of MOC Credit
CME Credit: Maximum of 1.0 hours of AMA PRA Category 1 Credit™
ACPE Credit: ACPE 1 knowledge-based contact hours of pharmacy CE
ACPE Number: 0221-9999-19-357-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss current treatment approaches to HBV and the existing unmet needs
discuss the current pipeline of novel agents for HBV therapy
discuss HBV diagnostics and study endpoints

Presentations:

8:00 AM - 9:00 AM
917 - From Inactive to Reactive: When and How to Treat HBV Infection
Marion G. Peters, MD – University of California, San Francisco
8:00 AM - 9:00 AM
918 - From Inactive to Reactive: When and How to Treat HBV Infection
Mark Sulkowski, MD – Johns Hopkins

Moderator(s)

Susanna Naggie, MD

Associate Professor
Duke University
Durham, North Carolina

Disclosure: Abbvie: Grant/Research Support
BioMarin: Consultant
FHI360: Consultant
Gilead Sciences: Grant/Research Support
PRA: Consultant
Tacere: Grant/Research Support
Vir Biotechnology: Consultant

Speaker(s)

MP

Marion Peters, MD

Emeritus Professor of Medicine
University of California, San Francisco
San Francisco, California

Disclosure: Abbott Molecular: Advisory Board
Roche: Employee
Mark Sulkowski, MD

Professor of Medicine
Johns Hopkins
Baltimore, MD

Disclosure: Arbutus: Advisory Board, Consultant
Assembly Bioscience: Research Grant
Gilead Sciences, Inc.: Advisory Board, Consultant, Research Grant